Study wrapper · #1361
Semaglutide improves markers of cardiovascular risk in people with HIV.
Editor's note
This is a secondary analysis of SLIM LIVER, a single-arm phase 2b trial, so there is no placebo group and only 36 selected responders were profiled — findings are mechanistic and hypothesis-generating. It is nonetheless the first lipidomic and lipoprotein/glycoprotein profiling reported during semaglutide therapy in any population. The disconnect between biomarker improvement and weight change is the interesting thread, dovetailing with cardiovascular-outcome trial analyses suggesting semaglutide's heart benefits are not fully explained by weight loss.
Plain-language abstract
In a sub-study of 36 people with HIV who lost weight on weekly 1 mg semaglutide, detailed blood profiling showed reductions in harmful fat species, cardiovascular-risk-linked lipoprotein particles, and inflammation markers — and these improvements did not simply track with how much weight or liver fat participants lost, hinting at an independent mechanism.